Business Wire

MA-CYBERARK

Share
CyberArk Named a Leader in 2022 Gartner Magic Quadrant for Access Management

CyberArk (NASDAQ: CYBR), the global leader in Identity Security, today announced it was named a Leader in the newly released 2022 Gartner® Magic Quadrant™ for Access Management1. This recognition follows CyberArk’s position as a Leader in the 2022 Gartner® Magic Quadrant™ for Privileged Access Management2, making it the only company to be recognized as a Leader in both reports.

“Today’s ever-escalating threat landscape calls for Identity Security leadership across multiple categories. It’s not enough to just manage identities. All types of identities must be secured, regardless of device, location or environment,” said Udi Mokady, founder, chairman and CEO, CyberArk. “We believe this recognition by Gartner further validates our strategy to deliver the industry’s most comprehensive Identity Security Platform, centered on privileged access management. CyberArk’s security-first approach is a differentiator for our business, and a critical value driver for our customers and partners.”

The CyberArk Identity Security Platform enables protection of any identity – human or machine – across the widest range of devices and environments from a single, comprehensive platform. It includes CyberArk Identity, which provides security-first access to thousands of business-critical applications and endpoints required by all users – employees, business partners, vendors and clients. CyberArk helps enterprises achieve heightened protection and enhanced productivity by applying intelligent privilege controls to the point of authentication, high-risk user sessions and more, across the entire identity lifecycle.

CyberArk continues to innovate to keep pace with customer needs. It recently unveiled new adaptive multi-factor authentication (MFA) and passwordless capabilities to provide additional defenses against attacks that rely on MFA fatigue to gain unauthorized access to protected systems. Additionally, CyberArk Identity Compliance extends the concepts of Zero Trust and least privilege to help ensure user access continually meets regulatory demands.

In the 2022 Gartner Magic Quadrant for Privileged Access Management, CyberArk was positioned both highest in Ability to Execute and furthest in Completeness of Vision for the fourth time in a row.

In addition to the latest recognition by Gartner, CyberArk continues to receive broad industry recognition for its Identity Security offerings. It was recently named an Overall Leader by KuppingerCole Analysts AG in the 2022 "Leadership Compass: Passwordless Authentication” report. According to the report, “CyberArk has established itself as a leader in Identity Security.” CyberArk also won the 2022 SC Award for Best Identity Management Solution.

CyberArk will also be hosting a global webinar, “Don't Just Manage Identities. Secure Them! Understanding CyberArk Identity Security and How to Apply It Across Your Organization,” on Wednesday, November 16, 2022. To register, visit: https://lp.cyberark.com/identity-security-defined-nov.html.

To download complimentary copies of both Gartner reports, visit: https://www.cyberark.com/gartner-magic-quadrant-reports-for-pam-and-access-management/

Gartner Disclaimers

GARTNER and MAGIC QUADRANT are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

1 – Gartner® Magic Quadrant for Access Management, by Henrique Teixeira, Abhyuday Data, Michael Kelley, James Hoover, Brian Guthrie, 1 November 2022
2 – Gartner® Magic Quadrant™ for Privileged Access Management, by Michael Kelley, James Hoover, Felix Gaehtgens, Abhyuday Data, 19 July 2022
3 – KuppingerCole Analysts AG, “Leadership Compass: Passwordless Authentication,” October 4, 2022 by Alejandro Leal

About CyberArk

CyberArk (NASDAQ: CYBR) is the global leader in Identity Security. Centered on privileged access management, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud workloads and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on Twitter via @CyberArk, LinkedIn or Facebook.

Copyright © 2022 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103006343/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release

The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release

Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release

Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye